Guangzhou Baiyunshan Pharmaceutical Holdings Temettü
Temettü kriter kontrolleri 3/6
Guangzhou Baiyunshan Pharmaceutical Holdings kazançlarla iyi bir şekilde karşılanan, mevcut getirisi 4.76% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi, temettüden önceki tarihi 15th November, 2024 olan 15th October, 2024 dir.
Anahtar bilgiler
4.8%
Temettü verimi
n/a
Geri Alım Getirisi
Toplam Hissedar Getirisi | n/a |
Gelecekteki Temettü Verimi | 4.6% |
Temettü Büyümesi | 15.2% |
Bir sonraki temettü ödeme tarihi | 15 Nov 24 |
Eski temettü tarihi | 15 Oct 24 |
Hisse başına temettü | HK$0.873 |
Ödeme oranı | 55% |
Son temettü güncellemeleri
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 874 şirketinin temettü ödemeleri son 10 yıldır dalgalı seyretti.
Büyüyen Temettü: 874 şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.
Piyasaya Karşı Temettü Getirisi
Guangzhou Baiyunshan Pharmaceutical Holdings Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (874) | 4.8% |
Pazarın Alt %25'i (HK) | 3.2% |
Pazarın En İyi %25'i (HK) | 7.9% |
Sektör Ortalaması (Healthcare) | 4.1% |
Analist tahmini (874) (3 yıla kadar) | 4.6% |
Önemli Temettü: 874 'in temettüsü ( 4.76% ), Hong Kong piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 3.25% ) daha yüksektir.
Yüksek Temettü: 874 'in temettüsü ( 4.76% ), Hong Kong piyasasındaki temettü ödeyenlerin en üst %25'ine ( 7.93% ) kıyasla düşüktür.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Makul ödeme oranı ( 54.6% ) ile 874 'un temettü ödemeleri kazançlarla karşılanmaktadır.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Yüksek nakit ödeme oranı ( 111.4% ) nedeniyle, 874 'un temettü ödemeleri nakit akışları tarafından yeterince karşılanmıyor.